ArticleArchives of public health = Archives belges de sante publique2025
Albumin-corrected anion gap and risk of mortality among US adults.
Article in Archives of public health = Archives belges de sante publique, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundElevated albumin-corrected anion gap (ACAG) has been linked to increased mortality across various patient populations, but its prognostic value in the general population remains unclear. This study examined the association between ACAG and all-cause, cardiovascular disease (CVD), and cancer mortality among US adults.
methodsData from 40,702 adults aged ≥ 20 years were analyzed from the National Health and Nutrition Examination Survey 1999-2018. ACAG was calculated as: anion gap + (4.4 - serum albumin [g/dL]) × 2.5. Cox proportional hazards models, restricted cubic splines, and Kaplan-Meier curves were used to assess associations. Subgroup and sensitivity analyses were conducted.
resultsOver a median 113 month follow-up, 6,087 deaths occurred, including 1,601 from CVD and 1,372 from cancer. Each 1-unit increase in ACAG was associated with higher risk of all-cause (HR = 1.08, 95% CI: 1.06-1.10), CVD (HR = 1.08, 95% CI: 1.05-1.12), and cancer mortality (HR = 1.06, 95% CI: 1.03-1.09). Participants in the highest ACAG quartile had significantly higher mortality risks compared to the lowest quartile. No evident nonlinear associations were observed for all-cause, CVD, and cancer mortality. The positive association with all-cause mortality was more pronounced among participants aged < 60 years, males, current smokers, and those with hyperlipidemia or diabetes. Sensitivity analyses confirmed robustness.
conclusionsElevated ACAG is independently associated with increased risks of all-cause, CVD, and cancer mortality in US adults. ACAG has potential value in stratifying mortality risk in public health contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.